About
10x Science builds frontier AI software that automates molecular-level characterization of protein therapeutics. It sells to pharmaceutical companies, biotechs, academic institutions, and other drug-development organizations, differentiating through deep-memory AI models and systems designed to process large volumes of spectral data and produce explainable, actionable results.
Market
10x Science competes in B2B life-sciences software for biologics and protein characterization, serving the analytical-development bottleneck that drug developers face before candidates reach the clinic. Its positioning is AI-native and automation-first: it applies frontier AI and deep-memory models to replace months of manual, error-prone analysis with scalable, real-time workflows that help teams advance the right candidates and stop the wrong ones early. Relative to established mass-spectrometry software vendors, its differentiation is a molecular-level, end-to-end AI platform rather than primarily instrument- or workflow-centered analysis software.
10x Science targets enterprise pharmaceutical and biotech drug-development teams, particularly scientists and analytical-development groups responsible for biologics and protein characterization. It also targets academic labs and core facilities performing protein analysis, as well as CROs seeking to scale analytical capabilities.
At a Glance
Problem
Drug developers need to understand protein therapeutics at the molecular level and connect molecular characteristics to functional outcomes, but the relevant analytical data can be extremely large and difficult to translate into clear decisions. The central pain is turning complex protein-characterization work into explainable, actionable insight quickly enough to guide development decisions.
The killer use case is drug development: helping biopharma teams identify the right protein candidates to advance and stop unsuitable candidates early. The economic logic is reducing the cost and risk of pursuing the wrong candidates, although the available research does not quantify the savings or describe the incumbent workflow in detail.
Product / Service
10x Science offers an AI-native protein-characterization platform for pharmaceutical companies, biotechs, and research institutions. It combines frontier AI models with deep memory, new algorithms, and an inference system designed to process terabytes of spectral data at the native binary level, characterize proteins molecularly, and connect those findings to functional outcomes.
The platform automates characterization and delivers explainable, actionable outputs in minutes rather than requiring developers to interpret the data manually over a longer cycle. Its models continuously improve as more data is analyzed, and the company says the platform is already live with biopharma, biotech, and academic institutions.
Market
10x Science competes in life-sciences platforms and tools, specifically the AI-native protein-characterization software category for biopharma. Its stated customer set spans pharmaceutical companies, biotechs, and research institutions. The available research does not identify named direct competitors, so a reliable company-by-company competitive comparison cannot be made from the evidence.
The company appears to be commercial rather than purely pre-revenue: Y Combinator describes strong commercial traction with enterprise pharma customers, and 10x Science says it is already working with biopharma, biotech, and academic institutions. It was founded in December 2025 and has raised a reported $4.8 million seed round led by Initialized; revenue figures were not disclosed in the available research.
Founders & Leadership
Funding History
Y Combinator
Initialized Capital
Recent News
Pulse2 reported that 10x Science had raised $4.8 million in seed funding for an AI platform focused on molecular-level protein characterization.
10x Science announced the closing of a $4.8 million seed round to develop frontier AI for molecular-level protein characterization across the life sciences. The company said it is expanding work with pharmaceutical and biotech partners.
TechCrunch covered 10x Science’s $4.8 million seed round and its effort to help pharmaceutical researchers understand complex molecules and determine which potential drug candidates matter.
HPCwire reported that 10x Science, a Y Combinator W26 company, raised $4.8 million in seed funding led by Initialized Capital to develop AI for molecular protein characterization.
10x Science described its AI-native software as technology for molecularly characterizing proteins at scale and enabling real-time analysis of complex scientific data.
Active Roles
1Business Model
10x Science appears to monetize through enterprise contracts for its AI-native protein-characterization platform, selling to biopharma, biotech, and academic customers. The company has not publicly disclosed specific pricing or whether contracts are subscription-, usage-, or services-based.